5 Key Takeaways
-
1
The RHONE-X study demonstrated the long-term safety and efficacy of faricimab for diabetic macular edema (DME) over four years.
-
2
More than 50% of patients receiving faricimab achieved a potential 20-week dosing interval by the end of the study.
-
3
BCVA and CST improvements observed in earlier studies were maintained throughout the four-year follow-up.
-
4
Patients switching from aflibercept to faricimab showed significant reductions in hard exudates, indicating improved disease management.
-
5
Faricimab was well tolerated, with a safety profile consistent with previous studies, supporting its long-term use in DME treatment.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
